Divalent metal transporter, iron, and Parkinson's disease: A pathological relationship

Cell Research

Volumn 20, Issue 4, 2010, Pages 397-399

  Lee, Hyun Pil ^a   Zhu, Xiongwei ^a   Liu, Gang ^b   Chen, Shu G ^a   Perry, George ^a,c   Smith, Mark A ^a   Lee, Hyoung Gon ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATION TRANSPORT PROTEIN; IRON; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2;

ARTICLE; HUMAN; METABOLISM; OXIDATIVE STRESS; PARKINSON DISEASE;

CATION TRANSPORT PROTEINS; HUMANS; IRON; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 77950533625     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2010.39     Document Type: Article

References (13)

1. Jiang H, Song N, Xu H, et al. Upregulation of divalent metal transporter in 6-hydroxydopamine intoxication is IRE/IRP dependent. Cell Res 2010; 20:345-356.
2. Christova T, Templeton DM. Effect of hypoxia on the binding and subcellular distribution of iron regulatory proteins. Mol Cell Biochem 2007; 301:21-32. (Pubitemid 46895143)
3. Gunshin H, Mackenzie B, Berger UV, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388:482-488. (Pubitemid 27328927)
4. Salazar J, Mena N, Hunot S, et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci USA 2008; 105:18578-18583.
5. Zheng W, Xin N, Chi ZH, et al. Divalent metal transporter 1 is involved in amyloid precursor protein processing and Abeta generation. FASEB J 2009; 23:4207-4217.
6. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997; 94:9866-9868. (Pubitemid 27408156)
7. Sayre LM, Perry G, Harris PL, et al. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 2000; 74:270-279. (Pubitemid 30012778)
8. Smith MA, Wehr K, Harris PL, et al. Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res 1998; 788:232-236. (Pubitemid 28202166)
9. Connor JR, Menzies SL, St Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 1992; 31:75-83.
10. Sangchot P, Sharma S, Chetsawang B, et al. Deferoxamine attenuates ironinduced oxidative stress and prevents mitochondrial aggregation and alphasynuclein translocation in SK-N-SH cells in culture. Dev Neurosci 2002; 24:143-153. (Pubitemid 36151444)
11. Cherny RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem 1999; 274:23223-23228. (Pubitemid 129529155)
12. Rottkamp CA, Raina AK, Zhu X, et al. Redox-active iron mediates amyloidbeta toxicity. Free Radic Biol Med 2001; 30:447-450. (Pubitemid 32155543)
13. Liu G, Men P, Perry G, Smith MA. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol Biol 2010; 610:123-144.